Insider · CIK 0001733614
Brian Koopman
Files at UTMD (UTAH MEDICAL PRODUCTS INC). First filing -, latest -.
Brian Koopman files SEC Form 4 as officer at UTMD (UTAH MEDICAL PRODUCTS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian Koopman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | UTMD UTAH MEDICAL PRODUCTS INC | GGift Common Stock | -50 | $66.27 | $3,314 | 782 | May 29, 2026 |
| Oct 31, 2025 | UTMD UTAH MEDICAL PRODUCTS INC | AGrant or award Employee Stock Option - Right to Buyderivative | +500 | $0.00 | $0 | 5,600 | Nov 25, 2025 |
| Sep 4, 2025 | UTMD UTAH MEDICAL PRODUCTS INC | GGift Common Stock | -50 | $62.75 | $3,138 | 832 | Sep 5, 2025 |
| Nov 1, 2024 | UTMD UTAH MEDICAL PRODUCTS INC | AGrant or award Employee Stock Option - Right to Buyderivative | +500 | $0.00 | $0 | 5,100 | Nov 8, 2024 |
Questions about Brian Koopman
Answered from the filings on this page, as of the latest one.
Is Brian Koopman buying or selling?
Brian Koopman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian Koopman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian Koopman has 0.
Where does Brian Koopman file Form 4?
Brian Koopman has filed Form 4 at UTMD (UTAH MEDICAL PRODUCTS INC) as Principal Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.